The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

Figure 4

Median percent change in select biomarkers with placebo, apremilast 20 mg BID, and apremilast 30 mg BID over Weeks 0 to 40.

(a) IL-17

(b) IL-23

(c) IL-6

(d) Ferritin

(e) IL-10

(f) IL-1RA

(g) TNF-α